Dato-DXd + Durvalumab + Pembrolizumab + Doxorubicin + Epirubicin + Cyclophosphamide + Paclitaxel + Carboplatin + Capecitabine + Olaparib
Phase 3Active 0 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Breast Cancer
Conditions
Breast Cancer
Trial Timeline
Nov 14, 2023 → Sep 23, 2032
NCT ID
NCT06112379About Dato-DXd + Durvalumab + Pembrolizumab + Doxorubicin + Epirubicin + Cyclophosphamide + Paclitaxel + Carboplatin + Capecitabine + Olaparib
Dato-DXd + Durvalumab + Pembrolizumab + Doxorubicin + Epirubicin + Cyclophosphamide + Paclitaxel + Carboplatin + Capecitabine + Olaparib is a phase 3 stage product being developed by Daiichi Sankyo for Breast Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT06112379. Target conditions include Breast Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Breast Cancer were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
17
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06112379 | Phase 3 | Active |
Competing Products
20 competing products in Breast Cancer